We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Liquidia Corporation (LQDA - Free Report) have lost 15.4% since the company reported second-quarter results on Aug. 11.
Liquidia reported second-quarter 2026 earnings of 74 cents per share, which beat the Zacks Consensus Estimate of 70 cents. The company reported a loss of 49 cents per share in the year-ago quarter.
Total revenues surged to $171.7 million from $8.8 million a year ago and surpassed the Zacks Consensus Estimate of $165 million, driven by continued adoption of its lead drug, Yutrepia.
Despite the earnings and revenue beats, investors appeared unimpressed, likely due to the relatively modest magnitude of the upside versus expectations.
The recent weakness has added to LQDA’s underperformance over the past month. Shares have lost 3.5% during this period compared to a 4.5% gain for the industry. The stock has also lagged the broader sector and the S&P 500 Index.
LQDA Underperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer examination of Liquidia’s key strengths and potential challenges could help investors determine whether the stock remains an attractive investment opportunity.
LQDA’s Yutrepia Gains Traction
Launched in June 2025, Yutrepia was approved by the FDA in May 2025 for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The drug is an inhaled dry-powder version of treprostinil made with the company’s proprietary PRINT technology, designed to deliver medicine deeper into the lungs through an easy-to-use inhaler and allow higher doses than other inhaled treprostinil treatments.
Yutrepia net product sales reached $170.4 million in the second quarter, up from $6.5 million a year earlier, driven by higher Yutrepia volume. Product sales increased 31.0% sequentially.
As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions since launch and started more than 5,000 patients on therapy.
More than 1,100 physicians had prescribed Yutrepia since its launch as of July 31, with more than 30% having written prescriptions for at least five patients. The prescription-to-start conversion rate remained above 85%.
Strong Yutrepia sales helped drive the company's fourth consecutive profitable quarter, with net income reaching $74.7 million in the second quarter.
Yutrepia appears to be gaining market share while expanding the inhaled prostacyclin market.
Liquidia currently generates revenues from sales of Yutrepia inhalation powder, and through a profit-sharing arrangement with Sandoz under a promotion agreement originally signed in August 2018 and subsequently amended. The agreement allows Liquidia to share in the profits generated from sales of Sandoz's generic Treprostinil Injection in the United States.
LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and Raynaud’s phenomenon associated with systemic sclerosis.
Liquidia is leveraging its expertise in respiratory and vascular diseases to advance a pipeline of novel therapies that could support long-term growth. A key pipeline asset is L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.
LQDA’s Overdependence on Yutrepia
While Yutrepia is driving LQDA’s top-line growth, the company remains heavily dependent on the drug as its primary growth driver. LQDA’s relatively lean pipeline further increases this concentration risk.
Liquidia is also involved in a patent dispute with United Therapeutics (UTHR - Free Report) over Yutrepia’s use in PH-ILD. Management said an adverse ruling could result in a royalty or other injunctive/adjunctive relief. A decision could come at any time, so this is a binary risk that could affect Yutrepia economics or commercialization.
LQDA’s Valuation and Estimate Movement
Going by the price/sales ratio, LQDA shares currently trade at 6.89X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97 and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.
Image Source: Zacks Investment Research
Avoid LQDA Stock Now
Liquidia's products and pipeline candidates for PAH compete across several established and clinically validated treatment pathways. UTHR markets four medicines in the United States to treat PAH, namely Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; under an in-license from Eli Lilly and Company) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.
Johnson & Johnson’s (JNJ - Free Report) Uptravi (selexipag) is approved to treat PAH. JNJ has another PAH drug in its portfolio, named Opsumit.
Despite Yutrepia’s strong launch, Liquidia’s investment case carries several risks. The company remains heavily dependent on Yutrepia, with a relatively lean pipeline, making any slowdown in prescriptions, reimbursement challenges or competitive pressure a significant threat to growth.
The ongoing patent litigation with UTHR over Yutrepia’s PH-ILD indication is another major overhang. Competition from established PAH therapies could also limit Yutrepia’s market-share gains.
While 2026 and 2027 EPS estimates have declined, rising R&D spending could pressure future profitability.
Overall, LQDA’s high dependence on Yutrepia, litigation risk, competitive pressures, elevated valuation and rising costs create an unfavorable risk-reward profile.
Hence, we advise current and prospective investors to avoid the stock for now.
View the Zacks #1 Rank List
Image: Bigstock
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Key Takeaways
Shares of Liquidia Corporation (LQDA - Free Report) have lost 15.4% since the company reported second-quarter results on Aug. 11.
Liquidia reported second-quarter 2026 earnings of 74 cents per share, which beat the Zacks Consensus Estimate of 70 cents. The company reported a loss of 49 cents per share in the year-ago quarter.
Total revenues surged to $171.7 million from $8.8 million a year ago and surpassed the Zacks Consensus Estimate of $165 million, driven by continued adoption of its lead drug, Yutrepia.
Despite the earnings and revenue beats, investors appeared unimpressed, likely due to the relatively modest magnitude of the upside versus expectations.
The recent weakness has added to LQDA’s underperformance over the past month. Shares have lost 3.5% during this period compared to a 4.5% gain for the industry. The stock has also lagged the broader sector and the S&P 500 Index.
LQDA Underperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer examination of Liquidia’s key strengths and potential challenges could help investors determine whether the stock remains an attractive investment opportunity.
LQDA’s Yutrepia Gains Traction
Launched in June 2025, Yutrepia was approved by the FDA in May 2025 for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The drug is an inhaled dry-powder version of treprostinil made with the company’s proprietary PRINT technology, designed to deliver medicine deeper into the lungs through an easy-to-use inhaler and allow higher doses than other inhaled treprostinil treatments.
Yutrepia net product sales reached $170.4 million in the second quarter, up from $6.5 million a year earlier, driven by higher Yutrepia volume. Product sales increased 31.0% sequentially.
As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions since launch and started more than 5,000 patients on therapy.
More than 1,100 physicians had prescribed Yutrepia since its launch as of July 31, with more than 30% having written prescriptions for at least five patients. The prescription-to-start conversion rate remained above 85%.
Strong Yutrepia sales helped drive the company's fourth consecutive profitable quarter, with net income reaching $74.7 million in the second quarter.
Yutrepia appears to be gaining market share while expanding the inhaled prostacyclin market.
Liquidia currently generates revenues from sales of Yutrepia inhalation powder, and through a profit-sharing arrangement with Sandoz under a promotion agreement originally signed in August 2018 and subsequently amended. The agreement allows Liquidia to share in the profits generated from sales of Sandoz's generic Treprostinil Injection in the United States.
LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and Raynaud’s phenomenon associated with systemic sclerosis.
Liquidia is leveraging its expertise in respiratory and vascular diseases to advance a pipeline of novel therapies that could support long-term growth. A key pipeline asset is L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.
LQDA’s Overdependence on Yutrepia
While Yutrepia is driving LQDA’s top-line growth, the company remains heavily dependent on the drug as its primary growth driver. LQDA’s relatively lean pipeline further increases this concentration risk.
Liquidia is also involved in a patent dispute with United Therapeutics (UTHR - Free Report) over Yutrepia’s use in PH-ILD. Management said an adverse ruling could result in a royalty or other injunctive/adjunctive relief. A decision could come at any time, so this is a binary risk that could affect Yutrepia economics or commercialization.
LQDA’s Valuation and Estimate Movement
Going by the price/sales ratio, LQDA shares currently trade at 6.89X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97 and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.
Image Source: Zacks Investment Research
Avoid LQDA Stock Now
Liquidia's products and pipeline candidates for PAH compete across several established and clinically validated treatment pathways. UTHR markets four medicines in the United States to treat PAH, namely Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; under an in-license from Eli Lilly and Company) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.
Johnson & Johnson’s (JNJ - Free Report) Uptravi (selexipag) is approved to treat PAH. JNJ has another PAH drug in its portfolio, named Opsumit.
Despite Yutrepia’s strong launch, Liquidia’s investment case carries several risks. The company remains heavily dependent on Yutrepia, with a relatively lean pipeline, making any slowdown in prescriptions, reimbursement challenges or competitive pressure a significant threat to growth.
The ongoing patent litigation with UTHR over Yutrepia’s PH-ILD indication is another major overhang. Competition from established PAH therapies could also limit Yutrepia’s market-share gains.
While 2026 and 2027 EPS estimates have declined, rising R&D spending could pressure future profitability.
Overall, LQDA’s high dependence on Yutrepia, litigation risk, competitive pressures, elevated valuation and rising costs create an unfavorable risk-reward profile.
Hence, we advise current and prospective investors to avoid the stock for now.
LQDA has a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.